According to a new study from the University of Michigan critically ill COVID-19 patients who received a single dose of tocilizumab intravenously were 45 per cent less likely to die overall. They were also more likely to be out of the hospital or off a ventilator one month after treatment compared with those who didn't receive the drug say researchers. This drug calms 'cytokine storm' or an overactive immune system that is caused by COVID-19 infection. The lower risk of death in patients who received intravenous tocilizumab happened despite the fact that they were also twice as likely to develop